Using the new Johnson & Johnson Covid-19 vaccine to create equity and trust

If the newly-approved one dose Johnson & Johnson COVID-19 vaccine is offered in low-income and minority communities in preference to their Pfizer and Moderna counterparts, will it be perceived as another slight by these communities due to questions surrounding it’s effectiveness?  Public health and bioethics experts Drs. Ruth Karron and Ruth Faden discuss an option that could avoid such misperceptions in this recent STAT First Opinion.

Translate »